Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing

Michlene Passeri; Elizabeth Matthews; Ryan Kammeyer; Amanda L Piquet

doi:10.3389/fneur.2022.972143

Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing

Front Neurol. 2022 Jul 28:13:972143. doi: 10.3389/fneur.2022.972143. eCollection 2022.

Authors

Michlene Passeri¹, Elizabeth Matthews¹, Ryan Kammeyer^{1

2}, Amanda L Piquet¹

Affiliations

¹ Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
² Department of Pediatrics and Neurology, Children's Hospital Anschutz Medical Campus, Aurora, CO, United States.

Abstract

Myelopathy is an increasingly recognized presentation of many antibody-mediated neuroinflammatory disorders. While specific features of certain autoimmune myelopathies such as aquaporin-4 antibody associated neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein associated disorder (MOGAD) are well-characterized, other less commonly seen antibody-associated myelopathies are not as well-defined. These include but are not limited to, Hu/ANNA1, anti-glial fibrillary acidic protein (GFAP), anti-CV2/collapsin response mediator protein (CRMP5), and amphiphysin. Here, we review the mentioned more common antibody mediated myelopathies as well those that as less common, followed by a review of differentials that may mimic these disorders.

Keywords: MOG antibody associated diseases; NMO spectrum disorder (NMOSD); autoimmune manifestations; myelitis; myelopathy; paraneoplastic syndrome (PNS).

Publication types

Review